AdaptHealth

Moat sources assessed via five lenses with relative weights: Switching costs (30%), Cost advantages (25%), Intangible assets (20%), Efficient scale (15%), Network effects (10%). 1) Switching costs (score 60): resupply programs, prescription management, and payer steerage create some inertia, especially in sleep therapy and oxygen.

The platform serves ~4.8 million patients annually via ~670 locations, supporting embedded referral relationships.

Still, payors can rebid or redirect and patients can be reassigned, limiting durability. 2) Cost advantages (score 55): national purchasing and shared operations (billing, logistics, digital myAPP) yield unit-cost efficiencies, but June 2026 guidance explicitly cited a manufacturer price increase that AdaptHealth could not fully pass through, evidencing constrained bargaining power. 3) Intangible assets (score 55): accreditation, payor contracts, clinical know‑how, and a broad referral base matter, but there is little brand premium in a reimbursement‑driven DME category. 4) Efficient scale (score 50): local market density helps routing, set‑ups and service times; however, DME markets sustain multiple regional players and scale advantages are not insurmountable.

The capitation model with a major integrated delivery network can confer territory exclusivity, but execution complexity is high. 5) Network effects (score 30): limited; more patients do not inherently increase value for other users beyond modest data/operating leverage.

Weighted outcome is a single‑moat profile with execution and reimbursement risks that cap durability.